Current Edition

Minimising Risk and Maximising Efficiency by taking a Strategic Approach to Comparative Trial Supply

Widely acknowledged to be a prerequisite for formulary listing and even successful licensure, comparator drugs and co-therapies are used within an estimated two-thirds of clinical trials. Nicholas Griffin at Almac Clinical Services evaluates how to minimise risk and increase efficiency when taking a strategic approach to comparative trial supply.